Anna Rull

Dr. Anna Rull

Infection and Immunity Research Group, IISPV, Hospital Universitari Joan XXIII, 4, 43005 Tarragona, Spain
orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 January 2013 in Cell Cycle
Verified
Journal Article
Open access
Javier A. MenendezJavier A. Menendez
Javier A. Menendez
Jorge JovenJorge Joven
Jorge Joven
Gerard AragonèsGerard Aragonès
Gerard Aragonès
Enrique Barrajon-CatalanEnrique Barrajon-Catalan
Enrique Barrajon-Catalan
Raúl Beltrán-DebónRaúl Beltrán-Debón
Raúl Beltrán-Debón
Antonio Segura-CarreteroAntonio Segura-Carretero
Antonio Segura-Carretero
Aging can be viewed as a quasi-programmed phenomenon driven by the overactivation of the nutrient-sensing mTOR gerogene. mTOR-driven aging can be triggered or accelerated by a decline or loss of re...

1 January 2013 in Mediators of Inflammation
Verified
Journal Article
Open access
PDF file
AHAnna Hernández-Aguilera
Anna Hernández-Aguilera
Anna RullAnna Rull
Anna Rull
EGEsther Rodríguez Gallego
Esther Rodríguez Gallego
MRMarta Riera-Borrull
Marta Riera-Borrull
FLFedra Luciano-Mateo
Fedra Luciano-Mateo
Jorge JovenJorge Joven
Jorge Joven
Obesity is not necessarily a predisposing factor for disease. It is the handling of fat and/or excessive energy intake that encompasses the linkage of inflammation, oxidation, and metabolism to the deleterious effects associated with the continuous excess of food ingestion. The roles of cytokines and insulin resistance in excessive energy intake have been studied extensively. Tobacco use and obesity accompanied by an unhealthy diet and physical inactivity are the main factors that underlie noncommunicable diseases. The implication is that the management of energy or food intake, which is the main role of mitochondria, is involved in the most common diseases. In this study, we highlight the importance of mitochondrial dysfunction in the mutual relationships between causative conditions. Mitochondria are highly dynamic organelles that fuse and divide in response to environmental stimuli, developmental status, and energy requirements. These organelles act to supply the cell with ATP and to synthesise key molecules in the processes of inflammation, oxidation, and metabolism. Therefore, energy sensors and management effectors are determinants in the course and development of diseases. Regulating mitochondrial function may require a multifaceted approach that includes drugs and plant-derived phenolic compounds with antioxidant and anti-inflammatory activities that improve mitochondrial biogenesis and act to modulate the AMPK/mTOR pathway.

19 April 2010 in Journal of Proteome Research
Verified
Journal Article
Closed access
MVMaria Vinaixa
Maria Vinaixa
MRMiguel Ángel Rodríguez-Gómez
Miguel Ángel Rodríguez-Gómez
Anna RullAnna Rull
Anna Rull
Raúl Beltrán-DebónRaúl Beltrán-Debón
Raúl Beltrán-Debón
CBCinta Blade
Cinta Blade
XCXavier Correig
Xavier Correig

1 July 2012 in Biochimica et Biophysica Acta (BBA) - General Subjects
Verified
Journal Article
Closed access
Jorge JovenJorge Joven
Jorge Joven
EEEugenia Espinel
Eugenia Espinel
Anna RullAnna Rull
Anna Rull
Gerard AragonèsGerard Aragonès
Gerard Aragonès
EGEsther Rodríguez Gallego
Esther Rodríguez Gallego
Raúl Beltrán-DebónRaúl Beltrán-Debón
Raúl Beltrán-Debón

1 January 2010 in Mediators of Inflammation
Verified
Journal Article
Open access
PDF file
Anna RullAnna Rull
Anna Rull
JCJordi Camps
Jordi Camps
CACarlos Alonso-Villaverde
Carlos Alonso-Villaverde
Jorge JovenJorge Joven
Jorge Joven
To maintain homeostasis under diverse metabolic conditions, it is necessary to coordinate nutrient-sensing pathways with the immune response. This coordination requires a complex relationship between cells, hormones, and cytokines in which inflammatory and metabolic pathways are convergent at multiple levels. Recruitment of macrophages to metabolically compromised tissue is a primary event in which chemokines play a crucial role. However, chemokines may also transmit cell signals that generate multiple responses, most unrelated to chemotaxis, that are involved in different biological processes. We have reviewed the evidence showing that monocyte chemoattractant protein-1 (MCP-1 or CCL2) may have a systemic role in the regulation of metabolism that sometimes is not necessarily linked to the traffic of inflammatory cells to susceptible tissues. Main topics cover the relationship between MCP-1/CCL2, insulin resistance, inflammation, obesity, and related metabolic disturbances.

20 April 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
CCCristina Colom
Cristina Colom
Anna RullAnna Rull
Anna Rull
Sanchez-Quesada José LuisSanchez-Quesada José Luis
Sanchez-Quesada José Luis
APAntonio Perez
Antonio Perez
Cardiovascular disease (CVD) is a major cause of mortality in type 1 diabetes mellitus (T1DM) patients, and cardiovascular risk (CVR) remains high even in T1DM patients with good metabolic control. The underlying mechanisms remain poorly understood and known risk factors seem to operate differently in T1DM and type 2 diabetes mellitus (T2DM) patients. However, evidence of cardiovascular risk assessment and management in T1DM patients often is extrapolated from studies on T2DM patients or the general population. In this review, we examine the existing literature about the prevalence of clinical and subclinical CVD, as well as current knowledge about potential risk factors involved in the development and progression of atherosclerosis in T1DM patients. We also discuss current approaches to the stratification and therapeutic management of CVR in T1DM patients. Chronic hyperglycemia plays an important role, but it is likely that other potential factors are involved in increased atherosclerosis and CVD in T1DM patients. Evidence on the estimation of 10-year and lifetime risk of CVD, as well as the efficiency and age at which current cardiovascular medications should be initiated in young T1DM patients, is very limited and clearly insufficient to establish evidence-based therapeutic approaches to CVD management.